Letter

Post-marketing surveillance is needed for off licence use of drugs in children

BMJ 2003; 326 doi: 10.1136/bmj.326.7391.712/a (Published 29 March 2003)
Cite this as: BMJ 2003;326:712.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Michael Tettenborn (mtettenborn@doctors.org.uk), consultant in paediatrics and child health
  1. Frimley Children's Centre, Frimley GU16 7AD

    EDITOR—Sutcliffe's editorial on the issue of testing pharmaceutical products in children addresses a longstanding problem for which there has been much talk but no solution.1 Although not likely to produce the quality of data that would come from formal trials in children, an alternative approach is to develop a …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular